Dear Reader,
As we approach the end of 2015, and publish our final issue of Drugs in R&D for the year, the editors and production staff at Adis wish to reflect on another successful year’s achievements and pay thanks to all those who have contributed their time and effort to guarantee the exceptional quality of our content.
We are delighted to have seen the conclusion of formalities surrounding the joint venture between Springer Science+Business Media and Nature Publishing Group, Palgrave Macmillan, Macmillan Education in early May. Substantial ground has already been made in the integration of business within the resulting Springer Nature company and we at Adis look eagerly toward the future, as the benefits of the collective expertise and capabilities of this company carry us forward.
The majority of our journals saw a rise in ISI impact factor against the previous year. Most notably, BioDrugs increased by 41 % to 2.989; the European Journal of Drug Metabolism and Pharmacokinetics increased 19 % to 1.563; CNS Drugs increased by 17 % to 5.113; Targeted Oncology increased 16 % to 4.000; Pediatric Drugs increased 15 % to 1.975; Drugs & Aging increased 13 % to 2.838; and Molecular Diagnosis & Therapy increased a further 12 % to 2.891, having already jumped 53 % in the preceding year. We hope to build upon these gains, once more, in 2016.
The Adis Book programme has grown substantially and 20 new titles will have been published over the course of the year. Over 50 further titles are currently in development with leading academics, internationally, and we continue to add more to the list. Our thanks, again, to all who have submitted these valuable proposals to date.
We offer our sincere thanks to all authors who have contributed articles to Drugs in R&D over the course of 2015. Their skill and dedication are critical to the continued publication of the journal. The world-class quality of published articles is, similarly, testament to the significant efforts of the peer reviewers, whose commitment ensures that our content is held to the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals who acted as reviewers for articles published in Drugs in R&D in 2015:
L. Abenavoli, Italy
Vajihe Akbari, Islamic Republic of Iran
Franz Allerberger, Austria
Abdul Basit, UK
Stefano Bellentani, Italy
Reiner R. Benecke, Germany
K. Blagoev, USA
Mehmet Celik, Turkey
Q. Chen, USA
Angela Colbers, The Netherlands
M. Contel, USA
R. Cristofoletti, Brazil
F. Dal Piaz, Italy
Richard O. Day, Australia
N. De Tommasi, Italy
Jasper Dingemanse, Switzerland
Michael Eadon, USA
Frank Edelmann, Germany
P. Ekmekci, Turkey
J. Friedly, USA
Anders Fuglsang, Denmark
G. Garbacz, Germany
A. Gurakar, USA
N. Guzzetta, USA
Richard I. Hall, Canada
Craig T. Hartrick, USA
N. Hasler-Nguyen, Switzerland
Don Hayes Jr, USA
Takumi Hirata, Japan
Sergio Iannazzo, Italy
S. Jackson-Rosario, USA
R. Jandhyala, UK
Wolfgang H. Jost, Germany
N. Kamata, Japan
Frank Kloprogge, UK
Roman Krawetz, Canada
S. Kumar, USA
M. Kusunoki, Japan
E. Kutoh, Japan
Jerrold H. Levy, USA
Joel Lexchin, Canada
A. Lonardo, Italy
Axel C. Mühlbacher, Germany
O. Majid, UK
Bimal Malhotra, USA
S. Mallayasamy, India
G. Marcovici, USA
T. Mizoshita, Japan
M. Monti, Italy
B. Mueller, USA
A. Nakajima, Japan
T. Nakane, Japan
Dag Nyholm, Sweden
Donna H. Odierna, USA
T. Ohkura, Japan
Vidya Perera, USA
Z. Pessetto, USA
A. Poole, Canada
E. Quinque, Germany
Simon W. Rabkin, Canada
M. Rana, USA
K. Rasmussen, UK
Bertold Renner, Germany
Paola Rogliani, Italy
Risto Roine, Finland
Lionel Rostaing, France
Matteo Ruggeri, Italy
G. Sahlem, USA
A. Sakuraba, Japan
Dahlia Salman, UK
F. Santini, Italy
Mark Sinyor, Canada
Edoardo Spina, Italy
A. Steib, France
N. Takahashi, Japan
Milton Teitler, USA
James E. Tisdale, USA
Yasuhiro Tsuji, Japan
C. Tziotzios, UK
Aziz Karim Valika, USA
Szende Vancea, Romania
Victor A. Voicu, Romania
M. Walter, Germany
L. Ward, Brazil
V. Wessagowit, Thailand
C. Wolf, UK
M. Wonnemann, Germany
We hope that you have found the articles published throughout 2015 to be both interesting and informative. The editors have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues in 2016.
With best wishes from the staff of Drugs in R&D and all at Adis Publications.
Rights and permissions
About this article
Cite this article
Acknowledgement to Referees. Drugs R D 15, 293–294 (2015). https://doi.org/10.1007/s40268-015-0115-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40268-015-0115-7